These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30348069)

  • 1. Passive-specific immunotherapy with monoclonal antibodies for prostate cancer: A systematic review.
    Khalili N; Keshavarz-Fathi M; Shahkarami S; Hirbod-Mobarakeh A; Rezaei N
    J Oncol Pharm Pract; 2019 Jun; 25(4):903-917. PubMed ID: 30348069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis.
    Calopedos RJS; Chalasani V; Asher R; Emmett L; Woo HH
    Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):352-360. PubMed ID: 28440324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for prostate cancer.
    Ilic D; Neuberger MM; Djulbegovic M; Dahm P
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.
    Paller CJ; Piana D; Eshleman JR; Riel S; Denmeade SR; Isaacsson Velho P; Rowe SP; Pomper MG; Antonarakis ES; Luo J; Eisenberger MA
    Prostate; 2019 Oct; 79(14):1597-1603. PubMed ID: 31361358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapies for prostate cancer against the prostate specific membrane antigen.
    Elsässer-Beile U; Bühler P; Wolf P
    Curr Drug Targets; 2009 Feb; 10(2):118-25. PubMed ID: 19199907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target antigens for prostate cancer immunotherapy.
    Saffran DC; Reiter RE; Jakobovits A; Witte ON
    Cancer Metastasis Rev; 1999; 18(4):437-49. PubMed ID: 10855787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
    Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
    Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.
    Tagawa ST; Milowsky MI; Morris M; Vallabhajosula S; Christos P; Akhtar NH; Osborne J; Goldsmith SJ; Larson S; Taskar NP; Scher HI; Bander NH; Nanus DM
    Clin Cancer Res; 2013 Sep; 19(18):5182-91. PubMed ID: 23714732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement.
    Murphy GP; Holmes EH; Boynton AL; Kenny GM; Ostenson RC; Erickson SJ; Barren RJ
    Prostate; 1995 Mar; 26(3):164-8. PubMed ID: 7534919
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers.
    Gong MC; Chang SS; Sadelain M; Bander NH; Heston WD
    Cancer Metastasis Rev; 1999; 18(4):483-90. PubMed ID: 10855791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
    Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG
    Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy for hormone-refractory prostate cancer.
    Shelley M; Harrison C; Coles B; Staffurth J; Wilt TJ; Mason MD
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005247. PubMed ID: 17054249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alternative tests to PSA for prostate cancer diagnosis].
    Defilippi E; Zitella A; Tizzani A
    Urologia; 2011; 78(2):75-81. PubMed ID: 21553390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific immunotherapy in hepatocellular cancer: A systematic review.
    Baradaran Noveiry B; Hirbod-Mobarakeh A; Khalili N; Hourshad N; Greten TF; Abou-Alfa GK; Rezaei N
    J Gastroenterol Hepatol; 2017 Feb; 32(2):339-351. PubMed ID: 27206802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer.
    Horn T; Krönke M; Rauscher I; Haller B; Robu S; Wester HJ; Schottelius M; van Leeuwen FWB; van der Poel HG; Heck M; Gschwend JE; Weber W; Eiber M; Maurer T
    Eur Urol; 2019 Oct; 76(4):517-523. PubMed ID: 30987843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of Prostate Specific Membrane Antigen Targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis.
    Tan N; Bavadian N; Calais J; Oyoyo U; Kim J; Turkbey IB; Mena E; Davenport MS
    J Urol; 2019 Aug; 202(2):231-240. PubMed ID: 30829130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection Rate of Prostate Specific Membrane Antigen Tracers for Positron Emission Tomography/Computerized Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis.
    Crocerossa F; Marchioni M; Novara G; Carbonara U; Ferro M; Russo GI; Porpiglia F; Di Nicola M; Damiano R; Autorino R; Cantiello F
    J Urol; 2021 Feb; 205(2):356-369. PubMed ID: 32935652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.